Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosisResearch in context
Matthew Lynch, Sophie Manoy, Peter D. Sly, Claire E. Wainwright et al. • EBioMedicine
(2025)
Summary: Background: Ataxia-telangiectasia (A-T) is a rare multisystem disease characterised by neurodegenerative cerebellar ataxia, lung disease, immune deficiency, high cancer risk, and mitochondrial dysfunction. A-T cells demonstrate de...
DOAJ
Open Access (DOAJ)
DOI:
10.1016/j.ebiom.2025.105840